Mortality Results from a Randomized Prostate-Cancer Screening Trial
Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Christine D. Berg(Prevention Group), Grant Izmirlian(National Institutes of Health), E. David Crawford(University of California San Diego), Philip C. Prorok(National Cancer Institute), John K. Gohagan(National Institutes of Health), Richard B. Hayes(New York University), Timothy R. Church(University of Minnesota), David Chia(University of California, Los Angeles), Edward P. Gelmann(University of Arizona), Paul F. Pinsky(National Cancer Institute), Anthony B. Miller(University of Toronto), Joel L. Weissfeld(University of Pittsburgh), Joshua M. Rathmell(National Institutes of Health), Saundra S. Buys(University of Utah), Mona N. Fouad(University of North Texas), Lance Yokochi(National Institutes of Health), Jonathan D. Clapp(National Institutes of Health), Robert L. Grubb, Douglas J. Reding(Ascension), Barnett S. Kramer(University of Pittsburgh), Barbara O’Brien(National Institutes of Health), Thomas L. Riley(Automation, Information, and Management Systems (United States)), Paul A. Kvale(Henry Ford Health System)
Cited by 2,929
Related Papers
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
|New England Journal of Medicine|1993|3.3k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
|New England Journal of Medicine|2013|1.4k
The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer
|New England Journal of Medicine|2000|1.4k